New study aims to wipe out aggressive breast cancer before surgery

NCT ID NCT06291064

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a specific chemotherapy combination (epirubicin + cyclophosphamide followed by docetaxel + carboplatin) in 85 Nigerian women with triple-negative breast cancer. The main goal is to see how many women have no cancer left in their breast or lymph nodes after treatment, before surgery. Researchers will also look for blood markers that might show if the cancer is resistant to chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Lagos State University Teaching Hospital
RECRUITING

Ikeja, Lagos, 100271, Nigeria
Lagos University Teaching Hospital
RECRUITING

Yaba, Lagos, 100254, Nigeria
Obafemi Awolowo University Teaching Hospitals Complex
RECRUITING

Ile-Ife, Osun State, 220005, Nigeria
University of Ibadan Hospital
RECRUITING

Ibadan, Oyo State, 200285, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.